Patients are either or both HPV positive and has cervical cell changes/dysplasia.
Conditions
Brief summary
Between groups, primary outcomes will be: • Scoring of the visibility of the SCJ by the colposcopist as TZ1, TZ2 and TZ3. • Representation of the TZ in at least 25% of the cervical biopsies from each patient described by the pathologist.
Detailed description
Between groups, secondary outcomes will be: • The patients' report on possible side effects during pretreatment. • The proportionen of CIN2+ found in biopsies. • The proportion of diagnostics conization. • Explore for each patient which biopsy represent the most severe histopathologic result by comparing the first biopsy with the other three.
Interventions
DRUGPlacebo til vagifem vaginal tablet 10 mikrogram.
DRUGVagifem 10 mikrogram vaginaltabletter
Sponsors
Region Midtjylland
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Between groups, primary outcomes will be: • Scoring of the visibility of the SCJ by the colposcopist as TZ1, TZ2 and TZ3. • Representation of the TZ in at least 25% of the cervical biopsies from each patient described by the pathologist. | — |
Secondary
| Measure | Time frame |
|---|---|
| Between groups, secondary outcomes will be: • The patients' report on possible side effects during pretreatment. • The proportionen of CIN2+ found in biopsies. • The proportion of diagnostics conization. • Explore for each patient which biopsy represent the most severe histopathologic result by comparing the first biopsy with the other three. | — |
Countries
Denmark
Outcome results
None listed